C4 Therapeutics develops drugs that remove disease-causing proteins from cells, with candidates in cancer and inflammation. CCCC reports earnings on Thu, Nov 5, 2026. In the past 30 days there were 3 dark pool prints.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 28 | Lake Street | Initiated | Buy | |
| Oct 9 | JP Morgan | Initiated | Buy | |
| Jun 1 | Evercore ISI Group | Maintained | Buy |
Seasonality
How CCCC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in CCCC in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CCCC is in one of them and how their past CCCC trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CCCC in an article yet. Here's the latest on the wider market.
About C4 Therapeutics
C4 Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts. It develops medicines based on targeted protein degradation, a process that removes disease-causing proteins from cells. Its most advanced drug candidates are being tested in cancers, including multiple myeloma and lung cancer, and it is also building programs for inflammation and neurological diseases. The company works with partners such as Merck KGaA, Roche and Pfizer on drug discovery and development.
- Headquarters
- Watertown, MA
- Founded
- 2015
- Website
- c4therapeutics.com ↗